Heron Therapeutics (HRTX) Tops Q4 EPS by 5c, provides guidance

Heron Therapeutics (NASDAQ: HRTX) reported Q4 EPS of $0.02, $0.05 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $40.78 million versus the consensus estimate of $37.3 million.

GUIDANCE:

Heron Therapeutics sees Q1 2025 revenue of $153-163 million, versus the consensus of $160.6 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Battery X Metals adds auto industry advisor to board
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance